<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569632</url>
  </required_header>
  <id_info>
    <org_study_id>ChildrensHRCOakland</org_study_id>
    <nct_id>NCT02569632</nct_id>
  </id_info>
  <brief_title>Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)</brief_title>
  <official_title>Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children's Hospital Oakland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the breadth of protection against meningococcal disease in humans&#xD;
      immunized with a newly FDA approved meningococcal B vaccine, trade name &quot;Trumenba®&quot;&#xD;
      manufactured by Pfizer Vaccines. As a secondary goal the investigators will investigate&#xD;
      underlying mechanisms by which human anti-FHbp antibodies elicit complement-mediated&#xD;
      bactericidal activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neisseria meningitidis causes meningitis and severe infections of the blood stream. The&#xD;
      incidence of serogroup B meningococcal disease however is too low to conduct a randomized,&#xD;
      controlled trial to determine the actual efficacy of the new serogroup B vaccines. Instead&#xD;
      vaccine efficacy was inferred from serum bactericidal antibody responses using four test&#xD;
      strains. However, because of strain variability of FHbp amino acid sequence (there are more&#xD;
      than 800 sequence variants described) and strain variability of FHbp expression, bactericidal&#xD;
      data on only four strains are unlikely to be sufficient to predict the actual strain coverage&#xD;
      by the vaccine. There also are gaps in knowledge about the underlying mechanisms by which&#xD;
      human antibodies to FHbp elicit complement mediated bactericidal activity. For example,&#xD;
      binding of FH to FHbp is specific for human FH. Therefore in vaccinated humans the vaccine&#xD;
      antigen is expected to form a complex with FH right after immunization. The investigators'&#xD;
      hypothesis is that binding of human FH to the vaccine antigen skews the antibody repertoire&#xD;
      to FHbp epitopes located outside of the FH combining site. The resulting antibodies would be&#xD;
      expected not to inhibit binding of FH to the bacteria. This hypothesis will be investigated&#xD;
      in Trumenba-immunized humans as part of studies in Aim 1 (and in future studies of&#xD;
      recombinant human anti-FHbp Fabs that will be enabled by obtaining DNA from individual B&#xD;
      cells, described in Aim 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breadth of Protective Activity of Serum Anti-FHbp Antibody Responses of Adults Immunized With Trumenba Vaccine as Assessed by Serum Bactericidal Titers</measure>
    <time_frame>18 months</time_frame>
    <description>Determine the percentage of subjects achieving serum bactericidal titers of 1:4 or greater in serum obtained 1 month after doses 2 and 3 as measured against a panel of 15 genetically diverse meningococcal strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Repertoire to FHbp</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the percentage of recombinant anti-FHbp Fabs isolated from B cells of each subject that react with 3 FHbp amino acid sequence variants representative of FHbp variant groups 1, 2 and 3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Open Label: MenB-FHbp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)</intervention_name>
    <description>All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.</description>
    <arm_group_label>Open Label: MenB-FHbp</arm_group_label>
    <other_name>MenB-FHbp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults in the following risk groups: physicians, nurses, respiratory therapists,&#xD;
             microbiology laboratory personnel working at UCSF Benioff Children's Hospital Oakland&#xD;
             or the University of Massachusetts Medical School as well as medical students&#xD;
             attending accredited U.S. medical schools&#xD;
&#xD;
          -  Able to comprehend and follow all required study procedures&#xD;
&#xD;
          -  In good health as determined by a brief medical history&#xD;
&#xD;
          -  For females of child bearing age a negative urine pregnancy test will be required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are not in the risk groups summarized above&#xD;
&#xD;
          -  Have not given or are unable to give written informed consent to participate in the&#xD;
             study&#xD;
&#xD;
          -  Females of child bearing potential who are pregnant, or planning on becoming pregnant&#xD;
             during the study period.&#xD;
&#xD;
          -  Persons with a past history of having Guillain-Barré Syndrome (GBS), or a family&#xD;
             history of GBS in a parent or sibling.&#xD;
&#xD;
          -  Persons with presence or suspected presence of serious chronic disease including but&#xD;
             not limited to: chronic cardiac disease, autoimmune disease, diabetes, hepatitis B/C,&#xD;
             HIV, progressive neurological disease or seizure, leukemia, lymphomas, or neoplasm.&#xD;
&#xD;
          -  Have participated in any other investigational drug or received any other vaccine&#xD;
             within the last 30 days.&#xD;
&#xD;
          -  Received a dose of a meningococcal serogroups A, C, Y, W conjugate vaccine within the&#xD;
             previous 30 days or wish to receive a dose of this vaccine during the six month study&#xD;
             period.&#xD;
&#xD;
          -  Have a history of anaphylactic shock, asthma, urticaria or other allergic reaction&#xD;
             after previous dose of Trumenba&#xD;
&#xD;
          -  Have experienced fever (oral temperature above 38.0°C) within the past 3 days or are&#xD;
             suffering from a present acute infectious disease&#xD;
&#xD;
          -  Are planning to leave the area of the study site before the end of the study period&#xD;
&#xD;
          -  Have obesity (BMI higher than 33); or 11.&#xD;
&#xD;
          -  With any condition which, in the opinion of the investigator, might interfere with the&#xD;
             evaluation of the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Granoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Oakland Research Institute, Center for Immunobiology and Vaccine Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine. Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00121-17. doi: 10.1128/CVI.00121-17. Print 2017 Aug.</citation>
    <PMID>28566335</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <results_first_submitted>May 10, 2017</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal Vaccines</keyword>
  <keyword>Neisseria Meningitidis</keyword>
  <keyword>Factor H-binding Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02569632/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label: MenB-FHbp</title>
          <description>Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)&#xD;
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals): All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The data from one subject enrolled in the study were excluded due to a diagnosis of cancer after dose 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Open Label: MenB-FHbp</title>
          <description>Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)&#xD;
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals): All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="17" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Breadth of Protective Activity of Serum Anti-FHbp Antibody Responses of Adults Immunized With Trumenba Vaccine as Assessed by Serum Bactericidal Titers</title>
        <description>Determine the percentage of subjects achieving serum bactericidal titers of 1:4 or greater in serum obtained 1 month after doses 2 and 3 as measured against a panel of 15 genetically diverse meningococcal strains.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label: MenB-FHbp</title>
            <description>Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)&#xD;
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals): All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Breadth of Protective Activity of Serum Anti-FHbp Antibody Responses of Adults Immunized With Trumenba Vaccine as Assessed by Serum Bactericidal Titers</title>
          <description>Determine the percentage of subjects achieving serum bactericidal titers of 1:4 or greater in serum obtained 1 month after doses 2 and 3 as measured against a panel of 15 genetically diverse meningococcal strains.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Repertoire to FHbp</title>
        <description>Determine the percentage of recombinant anti-FHbp Fabs isolated from B cells of each subject that react with 3 FHbp amino acid sequence variants representative of FHbp variant groups 1, 2 and 3</description>
        <time_frame>1 year</time_frame>
        <population>This was an exploratory objective requiring new technology. It was done on 0/17 subjects because of technical limitation.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label: MenB-FHbp</title>
            <description>Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)&#xD;
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals): All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Repertoire to FHbp</title>
          <description>Determine the percentage of recombinant anti-FHbp Fabs isolated from B cells of each subject that react with 3 FHbp amino acid sequence variants representative of FHbp variant groups 1, 2 and 3</description>
          <population>This was an exploratory objective requiring new technology. It was done on 0/17 subjects because of technical limitation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label: MenB-FHbp</title>
          <description>Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)&#xD;
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals): All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <description>One subject developed a severe local reactions after doses 1 and 2.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dan Granoff, MD (Principal Investigator)</name_or_title>
      <organization>Children's Hospital Oakland Research Institute (CHORI)</organization>
      <phone>510-428-3000 ext 7640</phone>
      <email>dgranoff@chori.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

